- New clinical candidate targets a GPCR and disease different from the first candidate disclosed in May 2019
- Demonstrates the combined power of StaR® technology and Structure-based Drug Design to assist in the creation of small molecules that modulate important disease targets
PR Newswire
TOKYO and LONDON, June 10, 2019